Skip to main content
    P

    Palisade Bio Inc (PALI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.01
    -0.02 (-1.94%)

    Market Cap: $201.01M

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Palisade Bio Inc (PALI) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Palisade Bio (PALI) has a market cap of $201.01M and an enterprise value of $87.40M. Its share count is up 2736.91% from a year earlier. Revenue grew 12400.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 56.52% below the market cap, as cash exceeds debt.

    Market Cap$201.01M
    Enterprise Value$87.40M
    Latest price (Nov 17, 2026)$1.01

    Key Dates

    The next earnings report is expected on Mar 18, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 18, 2027 (expected)
    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.31% in the quarter ended Sep 30, 2026 and grew 1088.75% a year over 2 years.

    Shares Outstanding212.03M
    Shares Change (YoY)+2736.91%
    Shares Change (QoQ)+0.31%
    Share Count Growth (2Y CAGR)+1088.75%

    Valuation Ratios

    Sales and book value multiples are 428.3x and 1.9x.

    P/S Ratio428.3x
    Forward P/S402.0x
    P/B Ratio1.9x

    Price Statistics

    The stock is down 52.80% over 52 weeks and trades 29.37% below its 50-day average.

    Beta (1Y)1.25
    52-Week Change-52.80%
    1-Month Change-24.63%
    3-Month Change-53.24%
    6-Month Change-44.20%
    5-Year Change-99.94%
    10-Year Change-100.00%
    Total Return (1Y)-52.80%
    Total Return (3Y CAGR)-51.89%
    Total Return (5Y CAGR)-77.49%
    Return vs SPY (1Y)-62.77%
    Max Drawdown (1Y)-63.93%
    Max Drawdown (3Y)-96.26%
    Sharpe Ratio (1Y)-0.82
    Correlation with SPY (1Y)0.20
    50-Day Average$1.43
    200-Day Average$1.82
    52-Week Range$1.01 to $2.86
    RSI (14 Days)31.6
    Average Volume (20 Days)3.69M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 20.16x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio20.16x
    Quick Ratio20.16x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -38.86% and return on assets is -36.86% over the last 12 months.

    Return on Equity (ROE)-38.86%
    Return on Assets (ROA)-36.86%
    Return on Capital Employed (ROCE)-38.76%
    ROIC (5Y Average)-10.23%
    Asset Turnover0.01x
    Receivables Turnover2.00x

    Scores

    PALI has an Altman Z-Score of 18.75, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score18.75
    Altman Z ZoneSafe
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue was $500.00K over the last 12 months.

    Revenue$500.00K
    Revenue Growth (YoY)+12400.00%
    Operating Income-$48.13M
    Pretax Income-$43.70M
    Net Income-$43.70M
    EBITDA-$43.69M
    EBIT-$43.69M
    Reported EPS (TTM)-$0.22

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 94.85% of the $118.55M in total assets.

    Cash and Equivalents$113.61M
    Total Debt$0
    Net Cash$113.61M
    Net Cash Per Share$0.54
    Working Capital$111.65M
    Shareholder Equity$112.44M
    Book Value Per Share$0.53
    Total Assets$118.55M
    Total Liabilities$6.11M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$26.40M
    FCF Per Share-$0.15

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -9625.40%.

    Operating Margin-9625.40%
    Pretax Margin-8739.20%
    Net Margin-8739.20%
    EBITDA Margin-8738.60%
    EBIT Margin-8738.60%

    Dividends and Yields

    PALI does not pay a dividend.

    Buyback Yield-61.26%
    Shareholder Yield-61.26%

    Stock Splits

    The last split was a 1-for-15 reverse split on Apr 8, 2024.

    Last Split DateApr 8, 2024
    Split TypeReverse split
    Split Ratio1:15

    Peer Position

    Against 9 similar companies, PALI has the 2nd highest P/S.

    P/S Ratio428.3x vs 19.1x median
    Revenue Growth (Trailing 4 Quarters, YoY)+12400.00% vs -57.30% median

    Competitors compared

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About PALI

    What is PALI's market cap?

    Palisade Bio has a market cap of $201.01M. Its enterprise value, which adds debt and subtracts cash, is $87.40M.

    How many shares of PALI are outstanding?

    Palisade Bio has 212.03M shares outstanding. The count is up 2736.91% from a year earlier.

    Does PALI pay a dividend?

    No. Palisade Bio does not pay a dividend.

    How much debt does PALI have?

    Palisade Bio has $0 of total debt and $113.61M of cash and equivalents, a net cash position of $113.61M.